ReviewCancers2021
Chemokines in the Landscape of Cancer Immunotherapy: How They and Their Receptors Can Be Used to Turn Cold Tumors into Hot Ones?
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer.JCI insight · 2022Pooled it
- Programmable microbial therapeutics: advances in engineered bacteria for targeted in vivo delivery and precision medicine.Journal of advanced research · 2026Review
- Identification of Cell Subpopulation-Specific Driver Genes Reveals Ideal Candidates for Renal Cell Carcinoma Immunotherapy.International journal of molecular sciences · 2026Article
- Towards the tumor microenvironment scoring methods for immune checkpoint inhibitor response.NPJ precision oncology · 2026Article
- Integrating chemokine signatures and multi-omic biomarkers to predict immunotherapy response in non-small cell lung cancer: a comprehensive narrative review.Frontiers in oncology · 2026Review
- Promoter Hypomethylation Unleashes HMGA1 to Orchestrate Immune Evasion and Therapy Resistance Across Cancers.Biology · 2025Article
- High‑dose sodium propionate contributes to tumor immune escape through the IGF2BP3/PD‑L1 axis in colorectal cancer.Oncology letters · 2025Article
- Chemokines: humble yet mighty players in the tumour microenvironment.Frontiers in immunology · 2025Review
- An immune-related gene pair signature predicts the prognosis and immunotherapeutic response in glioblastoma.Heliyon · 2024Article
- Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity.Nature nanotechnology · 2024Article
- The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review.European journal of medical research · 2024Review
- Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies.Frontiers in immunology · 2024Review
- PD-1 and CTLA-4 serve as major gatekeepers for effector and cytotoxic T-cell potentiation by limiting a CXCL9/10-CXCR3-IFNγ positive feedback loop.Frontiers in immunology · 2024Article
- CCR8 as a Therapeutic Novel Target: Omics-Integrated Comprehensive Analysis for Systematically Prioritizing Indications.Biomedicines · 2023Article
- Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- Article
- The chemokine monocyte chemoattractant protein-1/CCL2 is a promoter of breast cancer metastasis.Cellular & molecular immunology · 2023Review
- Evolution by innovation as a driving force to improve TCR-T therapies.Frontiers in oncology · 2023Review
- Emerging Roles of Chemokines in Cancer Immunotherapy.Cancers · 2022Article
- Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes.Cancers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the last decade, monoclonal antibodies to immune checkpoint inhibitors (ICI), also known as immune checkpoint blockers (ICB), have been the most successful approach for cancer therapy. Starting with mAb to cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors in metastatic melanoma and continuing with blockers of the interactions between program cell death 1 (PD-1) and its ligand program cell death ligand 1 (PDL-1) or program cell death ligand 2 (PDL-2), that have been approved for about 20 different indications. Yet for many cancers, ICI shows limited success. Several lines of evidence imply that the limited success in cancer immunotherapy is associated with attempts to treat patients with "cold tumors" that either lack effector T cells, or in which these cells are markedly suppressed by regulatory T cells (T
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.